Apellis Wins FDA Fast Track Designation for APL-2 in PNH

Apellis Pharmaceuticals scored an FDA Fast Track designation for APL-2 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

The candidate is intended for those who continue to experience hemolysis and require red blood cell transfusions, despite receiving therapy with eculizumab.